ChengDu Sheng Nuo Biotec (688117.SH) has signed a return and refund agreement, expected to reduce the company's net profit attributable to shareholders for the current year by RMB84.2466 million.

ChengDu Sheng Nuo Biotec (688117.SH) announced that U.S. customer A signed polypeptide API purchase orders with the company's wholly-owned subsidiary Sheng Nuo Pharmaceutical on February 6, 2025 and November 24, 2025, and paid the company a total of US$39.6588 million for the goods under the purchase orders. Affected by Sheng Nuo Pharmaceutical's inclusion on the U.S. Food and Drug Administration ("FDA") Import Alert 66-40 list, following joint consultation between the company and the customer, it was agreed to return part of the API already purchased, and the company refunded the corresponding payment of US$24.9596 million. After the refund under the agreement, the company expects to correspondingly reduce its main business revenue for the current year by RMB163 million, total profit by RMB99.1137 million, and net profit attributable to shareholders of the listed company by an estimated RMB84.2466 million. The above refund does not involve adjustments to the company's accounting data for the first three quarters of 2026 and prior years.